Phase 3 RCT in 3,689 healthy adults: 2-dose CYFENDUS (AV7909) met all primary immunogenicity endpoints for anthrax post-exposure prophylaxis, and was non-inferior and superior to 3-dose BioThrax on toxin-neutralising antibody response. Mostly grade 1-2 injection-site events.
RCTn = 3,689
Drobic et al. Immunogenicity, safety, and lot consistency of the anthrax vaccine adsorbed, adjuvanted for post-exposure prophylaxis of anthrax in healthy adults: A phase 3, randomized, double-blind trial